The Experts below are selected from a list of 82533 Experts worldwide ranked by ideXlab platform
Jennifer E. Ryder - One of the best experts on this subject based on the ideXlab platform.
-
Photodynamic Therapy and Topical Aminolevulinic Acid
American Journal of Clinical Dermatology, 2003Co-Authors: Aditya K. Gupta, Jennifer E. RyderAbstract:Photodynamic Therapy is a non-invasive technique used in the treatment of skin diseases which has various advantages, one being the ability to localize treatment to the area being treated, which is common among most photosensitizers. Aminolevulinic acid is a prodrug that is metabolized intracellularly to form the photosensitizing molecule protoporphyrin IX (PpIX). When PpIX is activated by light, cytotoxic reactive oxygen species and free radicals are generated. This phototoxic effect may cause malignant and non-malignant hyperproliferative tissue to be destroyed, to decrease in size, and to eventually disappear. The application of topical aminolevulinic acid 20% followed by the use of a blue light Photodynamic Therapy illuminator is indicated in the US for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. There are data suggesting that aminolevulinic acid/Photodynamic Therapy may also be beneficial in acne vulgaris, verrucae, psoriasis, mycosis fungoides, and human papillomavirus. This treatment modality has also proven effective in the management of skin cancer such as, Bowen disease and basal cell carcinoma. Further experience in the use of Photodynamic Therapy will help define its utility in the management of actinic keratosis and other dermatoses.
Aditya K. Gupta - One of the best experts on this subject based on the ideXlab platform.
-
Photodynamic Therapy and Topical Aminolevulinic Acid
American Journal of Clinical Dermatology, 2003Co-Authors: Aditya K. Gupta, Jennifer E. RyderAbstract:Photodynamic Therapy is a non-invasive technique used in the treatment of skin diseases which has various advantages, one being the ability to localize treatment to the area being treated, which is common among most photosensitizers. Aminolevulinic acid is a prodrug that is metabolized intracellularly to form the photosensitizing molecule protoporphyrin IX (PpIX). When PpIX is activated by light, cytotoxic reactive oxygen species and free radicals are generated. This phototoxic effect may cause malignant and non-malignant hyperproliferative tissue to be destroyed, to decrease in size, and to eventually disappear. The application of topical aminolevulinic acid 20% followed by the use of a blue light Photodynamic Therapy illuminator is indicated in the US for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. There are data suggesting that aminolevulinic acid/Photodynamic Therapy may also be beneficial in acne vulgaris, verrucae, psoriasis, mycosis fungoides, and human papillomavirus. This treatment modality has also proven effective in the management of skin cancer such as, Bowen disease and basal cell carcinoma. Further experience in the use of Photodynamic Therapy will help define its utility in the management of actinic keratosis and other dermatoses.
T J Dougherty - One of the best experts on this subject based on the ideXlab platform.
-
Photodynamic Therapy.
Journal of the National Cancer Institute, 1998Co-Authors: T J Dougherty, C J Gomer, B W Henderson, G Jori, D Kessel, M Korbelik, J Moan, Q PengAbstract:Photodynamic Therapy involves administration of a tumor-localizing photosensitizing agent, which may require metabolic synthesis (i.e., a prodrug), followed by activation of the agent by light of a specific wavelength. This Therapy results in a sequence of photochemical and photobiologic processes that cause irreversible photodamage to tumor tissues. Results from preclinical and clinical studies conducted worldwide over a 25-year period have established Photodynamic Therapy as a useful treatment approach for some cancers. Since 1993, regulatory approval for Photodynamic Therapy involving use of a partially purified, commercially available hematoporphyrin derivative compound (Photofrin) in patients with early and advanced stage cancer of the lung, digestive tract, and genitourinary tract has been obtained in Canada, The Netherlands, France, Germany, Japan, and the United States. We have attempted to conduct and present a comprehensive review of this rapidly expanding field. Mechanisms of subcellular and tumor localization of photosensitizing agents, as well as of molecular, cellular, and tumor responses associated with Photodynamic Therapy, are discussed. Technical issues regarding light dosimetry are also considered.
-
REVIEW Photodynamic Therapy
1998Co-Authors: T J Dougherty, C J Gomer, B W Henderson, G Jori, D Kessel, M Korbelik, J Moan, Q PengAbstract:Photodynamic Therapy involves administration of a tumorlocalizing photosensitizing agent, which may require metabolic synthesis (i.e., a prodrug), followed by activation of the agent by light of a specific wavelength. This Therapy results in a sequence of photochemical and photobiologic processes that cause irreversible photodamage to tumor tissues. Results from preclinical and clinical studies conducted worldwide over a 25-year period have established Photodynamic Therapy as a useful treatment approach for some cancers. Since 1993, regulatory approval for Photodynamic Therapy involving use of a partially purified, commercially available hematoporphyrin derivative compound (Photofrint )i n patients with early and advanced stage cancer of the lung, digestive tract, and genitourinary tract has been obtained in Canada, The Netherlands, France, Germany, Japan, and the United States. We have attempted to conduct and present a comprehensive review of this rapidly expanding field. Mechanisms of subcellular and tumor localization of photosensitizing agents, as well as of molecular, cellular, and tumor responses associated with Photodynamic Therapy, are discussed. Technical issues regarding light dosimetry are also considered. [J Natl Cancer Inst 1998;90:889‐905]
-
Photodynamic Therapy for the treatment of basal cell carcinoma
Archives of Dermatology, 1992Co-Authors: B. Dale Wilson, Thomas S. Mang, Howard Stoll, Cornelie M. Jones, Michele T. Cooper, T J DoughertyAbstract:• Background. —Photodynamic Therapy is an investigational method for the treatment of a variety of solid tumors. The purpose of this study was to determine the optimum factors and illustrate the effectiveness of Photodynamic Therapy in the treatment of basal cell carcinomas. This was a prospective study in which patients presenting with primary or recurrent basal cell tumors, particularly but not exclusively widespread tumors or large single tumors, were offered the option of Photodynamic Therapy in their treatment regimen. Results. —Patients were administered 1 mg/kg of a photosensitizer (Photofrin II). Light doses (630 nm) ranged from 72 to 288 J/cm 2 . A total of 37 patients with 151 sites were treated in this study. A complete response rate of 88% was achieved with one application. Morbidity was low; the most significant side effects were moderate pain and edema. Conclusions. —Photodynamic Therapy is a modality that offers localized treatment of primary or recurrent nonmelanoma skin cancer. By applying reciprocal doses of photosensitizer and light, the efficacy of Photodynamic Therapy in the treatment of skin lesions is demonstrated achieving significant light penetration into tissue with a high complete response rate of the lesions and acceptable normal tissue response.
Ketty Peris - One of the best experts on this subject based on the ideXlab platform.
-
Photodynamic Therapy for basal cell carcinoma
Future Oncology, 2015Co-Authors: Maria Concetta Fargnoli, Ketty PerisAbstract:Topical Photodynamic Therapy is an effective and safe noninvasive treatment for low-risk basal cell carcinoma, with the advantage of an excellent cosmetic outcome. Efficacy of Photodynamic Therapy in basal cell carcinoma is supported by substantial research and clinical trials. In this article, we review the procedure, indications and clinical evidences for the use of Photodynamic Therapy in the treatment of basal cell carcinoma.
David H. Abramson - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of choroidal melanoma using Photodynamic Therapy.
American Journal of Ophthalmology, 2003Co-Authors: Irene A. Barbazetto, Indira S. Rollins, Stanley Chang, David H. AbramsonAbstract:Abstract Purpose To InternetAdvance publication at ajo.com Feb 26, 2002. investigate the effect of Photodynamic Therapy using verteporfin on choroidal melanoma. Design Interventional case series. Methods Four patients with choroidal melanoma who showed recurrence or no response after previous brachyTherapy and transpupillary thermoTherapy were treated with Photodynamic Therapy. Results One tumor decreased in size and remained stable for 18 months. One tumor had no growth for 11 months. Two melanomas continued to grow, necessitating enucleation. Conclusion Of the four eyes that had failed conventional therapies, two would have been salvaged (to date) with Photodynamic Therapy. However, additional studies are needed to determine if Photodynamic Therapy can play a role in the management of choroidal melanoma.